A Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine

Completed

• Conditions: Diabetes Mellitus, Type 2
• Interventions: Drug: Insulin detemir

• Registration Number: NCT03960814
• Lead Sponsor: Novo Nordisk A/S

Brief Summary

This study will examine the influence of the basal insulins detemir and glargine on risk of cardiovascular death and death from all causes in patients treated by their general practitioner in United Kingdom (UK). The data for this study will be drawn from the Clinical Practice Research Datalink (CPRD) Register.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-05-21
• Study First Submitted: 2019-05-21
• Study First Submitted QC: 2019-05-21
• Study First Posted: 2019-05-23
• Primary Completion: 2019-06-07
• Study Completion: 2019-06-07
• Status Verified: 2019-07
• Last Update Submitted: 2019-07-16
• Last Update Posted: 2019-07-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 12847

Inclusion Criteria

• Diagnosis (ever) of type 2 diabetes
• Prescription (ever) of basal insulins glargine or detemir
• Insulin-naïve until initiation of basal insulins glargine or detemir
• Aged 40 years or older at start of observation period

Exclusion Criteria

• Diagnosis of type 1 diabetes

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Cohort 1	Insulin detemir	New users of basal insulins glargine and detemir

Primary Outcome Measures

Name	Time	Method
Age at all cause death or censoring	Observation period 2004 - 2018	Years
Age at death of cardiovascular disease	Observation period 2004 - 2018	Years

Trial Locations

Locations (1)

Novo Nordisk Investigational Site; 🇩🇰 Bagsværd, Denmark